Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Rhea-AI Summary

DBV Technologies has released its Half-Year Report for the liquidity contract with ODDO BHF, detailing financial transactions and asset management as of June 30, 2022. The liquidity account holds 106,287 shares valued at €430,854.35. Since the contract's inception in July 2018, resources have slightly decreased from 41,159 shares and €432,367.25 initially. In the first half of 2022, 706 purchases and 869 sales were made, with total volumes of €1,056,560.18 for purchases and €1,311,871.05 for sales.

Positive

• Liquidity account contains 106,287 shares valued at €430,854.35.
• Increased trading activity with 706 purchases and 869 sales executed in H1 2022.
• Strong total volumes: €1,056,560.18 for purchases and €1,311,871.05 for sales.

Negative

• Decrease in liquidity account value from €432,367.25 since July 2018.
• Net sales exceeded purchases, indicating possible liquidity pressure.

AMF REGULATED INFORMATION
Montrouge, France, July 27, 2022

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

As of June 30, 2022, the following assets appeared on the liquidity account:

• 106,287 DBV Technologies shares;
• € 430,854.35.

Upon signing the liquidity contract in July 2018, the following resources appeared on the liquidity account:

• 41,159 DBV Technologies ordinary shares;
• € 432,367.25.

Number of transactions executed during the first half-year of 2022:

• Purchase: 706
• Sale: 869

Over the same period, the volumes traded represented:

• 345,064 DBV Technologies ordinary shares purchased for €1,056,560.18
• 392,408 DBV Technologies ordinary shares sold for €1,311,871.05

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Viaskin and EPIT are trademarks of DBV Technologies.

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

What is the current liquidity account status of DBV Technologies?

As of June 30, 2022, DBV Technologies' liquidity account holds 106,287 shares valued at €430,854.35.

How many shares were traded by DBV Technologies in the first half of 2022?

During the first half of 2022, DBV Technologies executed 706 purchases and 869 sales.

What were the total trading volumes for DBV Technologies in H1 2022?

The total trading volumes for DBV Technologies in H1 2022 amounted to €1,056,560.18 for purchases and €1,311,871.05 for sales.

How has DBV Technologies' liquidity account changed since 2018?

Since signing the liquidity contract in July 2018, the liquidity account value has decreased from €432,367.25.